Source comparison
MK-677 for Fat Loss Research Evidence: Study Design Comparison
| Study | Duration | Dose | Subject Population | Fat Mass Change | Lean Mass Change | Professional Assessment ||—|—|—|—|—|—|| Murphy et al. (1998) JCEM | 12 months | 25mg daily | Healthy older adults (n=24) | −1.1kg vs placebo | +1.8kg | Statistically signific
This comparison does not assign a generated winner or score.
- | Study | Duration | Dose | Subject Population | Fat Mass Change | Lean Mass Change | Professional Assessment ||—|—|—|—|—|—|| Murphy et al. (1998) JCEM | 12 months | 25mg daily | Healthy older adults (n=24) | −1.1kg vs placebo | +1.8kg | Statistically significant recomposition, clinically modest fat loss without dietary control || Chapman et al. (1996) | 24 months | 12.5mg and 25mg daily | GH-deficient adults (n=65) | −0.9kg (12.5mg), −1.5kg (25mg) | +2.7kg (12.5mg), +4.3kg (25mg) | Dose-dependent lean mass gains, fat loss secondary to improved partitioning || Svensson et al. (1998) | 9 weeks | 25mg daily | Obese males (n=8) | −0.3kg (not significant) | +0.9kg | Short duration limits observable fat loss; appetite increase noted || Nass et al. (2008) JCEM | 12 months | 25mg daily | Older adults post-hip fracture (n=123) | −0.8kg vs placebo | +1.6kg | Lean mass preservation during recovery; fat loss minimal without activity |